Pascal Biosciences to Present at 2019 BIO International Convention
29 Mayo 2019 - 7:30AM
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or
the “Company”), a drug discovery and development company, today
announced the Company will present at the upcoming BIO
International Convention taking place June 3-6 at the Pennsylvania
Convention Center in Philadelphia. The BIO International Convention
is the premier annual meeting for biotech and pharma, with more
than 16,000 attendees gathering for partnering and networking
opportunities.
Kevin Egan, VP Business Development at Pascal,
will provide a corporate overview presentation highlighting the
Company’s therapeutic pipeline on Tuesday, June 4 at 4:30 p.m. EDT
in Theater 2, Level 200. Mr. Egan will describe recent advances in
Pascal’s PAS-403 program for glioblastoma, which is advised by a
world class group of neuro-oncologists. In addition, advances for
PAS-393, a cannabinoid for enhancing immune checkpoint inhibitors
for cancer, will also be presented.
Members of the Pascal management team will be
available for meetings during the BIO International Convention. To
arrange a meeting with management, please contact
bd@pascalbiosciences.com or visit the BIO One-one-One Partnering
webpage to schedule a meeting directly.
About Pascal Biosciences Inc.
Pascal Biosciences is a biotechnology company
focused on advancing innovative approaches for the treatment of
cancer. Pascal is directed by a strong group of seasoned veterans
of the biotech industry—these experts have started more than ten
successful companies and also have discovered five approved
therapeutics. The company’s leading portfolio includes
cannabinoid-based therapeutics and targeted therapies. A small
molecule therapeutic, PAS-403, is advancing into clinical trials
for the treatment of glioblastoma, and the immuno-stimulatory
cannabinoid PAS-393 will be used in combination with checkpoint
inhibitor therapy. In addition, Pascal is developing a B-cell
targeted antibody for acute lymphoblastic leukemia. For more
information, visit www.pascalbiosciences.com.
Investors: invest@pascalbiosciences.com
Media Contact: Julie
Rathbuninfo@pascalbiosciences.com Tel: 206-769-9219
DISCLAIMER Certain statements in this press
release contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including
without limitation statements containing the words “believe”,
“may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Such forward-looking
statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
events or developments, or industry results, to be materially
different from any future results, events or developments express
or implied by such forward-looking statements or information. Such
factors include, among others, our stage of development, lack of
any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining
regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and
the prospects for negotiating additional corporate collaborations
or licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information,
which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are
based on our current expectations and we undertake no obligation to
revise or update such forward- looking statements and information
to reflect subsequent events or circumstances, except as required
by law.“Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release”
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Pascal Biosciences (TSXV:PAS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024